Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Randomized, Placebo- Controlled Trial of Vigabatrin for Short Term Abstinence From Cocaine in Cocaine Dependent Parolees
Brief Summary: The primary objective of this study is to assess the efficacy of vigabatrin for the treatment of cocaine dependence, based on the twice-weekly qualitative urine toxicologies for cocaine. Based on two prior unblinded human studies and 15 years of animal studies, this 100 subject double- blind, randomized study is designed to show if with vigabatrin treatment but not placebo, even non-hospitalized cocaine dependent individuals with ready access to cocaine will become cocaine abstinent if they are self motivated to stop their cocaine habit. To accomplish this, cocaine dependent subjects will be randomly assigned to either a placebo or vigabatrin treatment group and treated for a nine week period. The primary hypothesis is that as compared to the placebo arm, the vigabatrin treatment arm will show a significant increase in the number of subjects who are abstinent for the final 3 weeks of the study.


Options:
A: Arm Label: Lithium plus Divalproex; Type: EXPERIMENTAL; Interventions: Drug: Lithium, Drug: Divalproex | Arm Label: Lithium plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lithium, Drug: Placebo | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): Lithium plus Divalproex, Lithium plus placebo | Intervention Type: DRUG; Name: Divalproex; Assigned to Arm(s): Lithium plus Divalproex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Lithium plus placebo
B: Arm Label: Topiramate; Type: EXPERIMENTAL; Interventions: Drug: Topiramate + Cognitive Behavioral Therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Cognitive Behavioral Therapy | Intervention Type: DRUG; Name: Topiramate + Cognitive Behavioral Therapy; Assigned to Arm(s): Topiramate | Intervention Type: DRUG; Name: Placebo + Cognitive Behavioral Therapy; Assigned to Arm(s): Placebo
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vigabatrin, Behavioral: Group therapy | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Group therapy | Intervention Type: DRUG; Name: Vigabatrin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B | Intervention Type: BEHAVIORAL; Name: Group therapy; Assigned to Arm(s): A, B
D: Arm Label: 1 topiramate + CR; Type: EXPERIMENTAL; Interventions: Drug: topiramate, Behavioral: Contingency Reinforcement | Arm Label: 2 topiramate + NonCR; Type: EXPERIMENTAL; Interventions: Drug: topiramate | Arm Label: 4 Placebo + NonCR; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo + NonCR | Arm Label: 3 Placebo + CR; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Reinforcement | Intervention Type: DRUG; Name: topiramate; Assigned to Arm(s): 1 topiramate + CR, 2 topiramate + NonCR | Intervention Type: BEHAVIORAL; Name: Contingency Reinforcement; Assigned to Arm(s): 1 topiramate + CR, 3 Placebo + CR | Intervention Type: DRUG; Name: placebo + NonCR; Assigned to Arm(s): 4 Placebo + NonCR

Answer: C